Safety and Efficacy Study of EPI-743 on Visual Function in Patients With Friedreich's Ataxia

Trial Profile

Safety and Efficacy Study of EPI-743 on Visual Function in Patients With Friedreich's Ataxia

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Vatiquinone (Primary)
  • Indications Friedreich's ataxia
  • Focus Therapeutic Use
  • Sponsors Edison Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2017 Primary endpoint of Visual Function has not been met, according to results presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
    • 18 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top